CD8A and COVID-19: First of all, the present detailed systematic review and meta-analysis exploring the latest clinical evidence for immunological profiles of COVID-19 patients treated with oral CHM as an adjuvant, would be beneficial for us to understand the lesser-known roles of CHM on lymphocyte, CD3+, CD4+, CD4+/CD8+, and TNF-α, which will deepen our insights into COVID-19 treatments.